Jin Yang Pharmaceutical (A007370) 주식 개요진양제약은 한국에서 제약 사업을 영위하는 기업입니다. 자세히 보기A007370 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적1/6재무 건전성1/6배당1/6강점주가수익률(2.2x)이 KR 시장(11.5x)보다 낮습니다.위험 분석이자 지급액이 수익으로 잘 충당되지 않음재무 결과에 영향을 미치는 대규모 일회성 항목의미 있는 시가총액이 없습니다(₩50B)모든 위험 점검 보기A007370 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW498,716 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG498,716 investors already sharing narrativesYour Fair Value₩Current Price₩3.88k56.2% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-7b269b2016201920222025202620282031Revenue ₩269.2bEarnings ₩49.1bAdvancedSet Fair ValueView all narrativesJin Yang Pharmaceutical Co., Ltd. 경쟁사MYUNGMOON PharmLtdSymbol: KOSE:A017180Market cap: ₩42.3bKukje PharmaSymbol: KOSE:A002720Market cap: ₩68.5bRP BioSymbol: KOSDAQ:A314140Market cap: ₩49.4bTheragen EtexLtdSymbol: KOSDAQ:A066700Market cap: ₩73.7b가격 이력 및 성과Jin Yang Pharmaceutical 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₩3,875.0052주 최고가₩6,890.0052주 최저가₩3,350.00베타0.331개월 변동-7.07%3개월 변동-12.33%1년 변동-40.48%3년 변동-36.06%5년 변동-42.42%IPO 이후 변동95.31%최근 뉴스 및 업데이트분석 기사 • May 27Beyond Lackluster Earnings: Potential Concerns For Jin Yang Pharmaceutical's (KOSDAQ:007370) ShareholdersJin Yang Pharmaceutical Co., Ltd.'s ( KOSDAQ:007370 ) stock wasn't much affected by its recent lackluster earnings...Buy Or Sell Opportunity • May 14Now 22% overvaluedOver the last 90 days, the stock has fallen 6.1% to ₩4,695. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 22%.Buy Or Sell Opportunity • Apr 13Now 20% overvaluedOver the last 90 days, the stock has fallen 4.6% to ₩4,625. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 22%.New Risk • Mar 27New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 3,533% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩59.6b market cap, or US$39.4m).Buy Or Sell Opportunity • Mar 20Now 21% overvaluedOver the last 90 days, the stock has fallen 12% to ₩4,640. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 22%.Buy Or Sell Opportunity • Mar 05Now 20% overvaluedOver the last 90 days, the stock has fallen 12% to ₩4,630. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 22%.더 많은 업데이트 보기Recent updates분석 기사 • May 27Beyond Lackluster Earnings: Potential Concerns For Jin Yang Pharmaceutical's (KOSDAQ:007370) ShareholdersJin Yang Pharmaceutical Co., Ltd.'s ( KOSDAQ:007370 ) stock wasn't much affected by its recent lackluster earnings...Buy Or Sell Opportunity • May 14Now 22% overvaluedOver the last 90 days, the stock has fallen 6.1% to ₩4,695. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 22%.Buy Or Sell Opportunity • Apr 13Now 20% overvaluedOver the last 90 days, the stock has fallen 4.6% to ₩4,625. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 22%.New Risk • Mar 27New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 3,533% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩59.6b market cap, or US$39.4m).Buy Or Sell Opportunity • Mar 20Now 21% overvaluedOver the last 90 days, the stock has fallen 12% to ₩4,640. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 22%.Buy Or Sell Opportunity • Mar 05Now 20% overvaluedOver the last 90 days, the stock has fallen 12% to ₩4,630. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 22%.Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩4,370, the stock trades at a trailing P/E ratio of 10.2x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 26% over the past three years.공시 • Feb 24Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2026Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 34, sinpyeong-ro, jijeong-myeon, gangwon-do, wonju South KoreaUpcoming Dividend • Dec 22Upcoming dividend of ₩150 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 20 April 2026. Trailing yield: 2.8%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%).New Risk • Nov 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.7% Last year net profit margin: 25% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (3.7% operating cash flow to total debt). Minor Risks Profit margins are more than 30% lower than last year (4.7% net profit margin). Market cap is less than US$100m (₩61.9b market cap, or US$42.1m).Declared Dividend • Nov 08Dividend of ₩150 announcedDividend of ₩150 is the same as last year. Ex-date: 29th December 2025 Payment date: 20th April 2026 Dividend yield will be 2.9%, which is higher than the industry average of 1.1%. Sustainability & Growth The dividend has increased by an average of 11% per year over the past 4 years and payments have been stable during that time.공시 • Nov 07Jin Yang Pharmaceutical Co., Ltd. announces Annual dividend, payable on April 20, 2026Jin Yang Pharmaceutical Co., Ltd. announced Annual dividend of KRW 150.0000 per share payable on April 20, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.분석 기사 • May 24We Think Shareholders Should Be Aware Of Some Factors Beyond Jin Yang Pharmaceutical's (KOSDAQ:007370) ProfitDespite posting strong earnings, Jin Yang Pharmaceutical Co., Ltd.'s ( KOSDAQ:007370 ) stock didn't move much over the...공시 • Feb 25Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 20, 2025Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 20, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 34, sinpyeong-ro, jijeong-myeon, gangwon-do, wonju South Korea분석 기사 • Jan 06Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370) Soars 39% But It's A Story Of Risk Vs RewardDespite an already strong run, Jin Yang Pharmaceutical Co., Ltd. ( KOSDAQ:007370 ) shares have been powering on, with a...New Risk • Jan 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (70% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (5.9% increase in shares outstanding). Market cap is less than US$100m (₩89.7b market cap, or US$61.5m).Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improves as stock rises 35%After last week's 35% share price gain to ₩7,850, the stock trades at a trailing P/E ratio of 3.2x. Average trailing P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 21% over the past three years.Declared Dividend • Dec 19Dividend of ₩150 announcedShareholders will receive a dividend of ₩150. Ex-date: 27th December 2024 Payment date: 1st January 1970 Dividend yield will be 2.5%, which is higher than the industry average of 1.1%. Sustainability & Growth The dividend has increased by an average of 14% per year over the past 3 years and payments have been stable during that time.Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩6,180, the stock trades at a trailing P/E ratio of 2.5x. Average trailing P/E is 12x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 3.0% over the past three years.분석 기사 • Nov 22Shareholders Shouldn’t Be Too Comfortable With Jin Yang Pharmaceutical's (KOSDAQ:007370) Strong EarningsEven though Jin Yang Pharmaceutical Co., Ltd. ( KOSDAQ:007370 ) posted strong earnings recently, the stock hasn't...Reported Earnings • Nov 15Third quarter 2024 earnings released: EPS: ₩2,008 (vs ₩363 in 3Q 2023)Third quarter 2024 results: EPS: ₩2,008 (up from ₩363 in 3Q 2023). Revenue: ₩31.6b (up 31% from 3Q 2023). Net income: ₩22.2b (up 468% from 3Q 2023). Profit margin: 70% (up from 16% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.New Risk • Aug 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 9.5% Last year net profit margin: 18% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (11% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (9.5% net profit margin). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Market cap is less than US$100m (₩64.1b market cap, or US$48.0m).분석 기사 • Aug 19Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370) Shares Fly 32% But Investors Aren't Buying For GrowthDespite an already strong run, Jin Yang Pharmaceutical Co., Ltd. ( KOSDAQ:007370 ) shares have been powering on, with a...Valuation Update With 7 Day Price Move • Aug 19Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₩7,250, the stock trades at a trailing P/E ratio of 6.8x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 1.8% over the past three years.New Risk • Aug 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Market cap is less than US$100m (₩62.0b market cap, or US$45.9m).분석 기사 • Aug 12These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Reasonably WellHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • May 23Jin Yang Pharmaceutical's (KOSDAQ:007370) Problems Go Beyond Weak ProfitThe subdued market reaction suggests that Jin Yang Pharmaceutical Co., Ltd.'s ( KOSDAQ:007370 ) recent earnings didn't...New Risk • Mar 16New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Market cap is less than US$100m (₩63.8b market cap, or US$48.0m).Upcoming Dividend • Dec 20Upcoming dividend of ₩150 per share at 2.4% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 19 April 2024. Trailing yield: 2.4%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩363 (vs ₩560 in 3Q 2022)Third quarter 2023 results: EPS: ₩363 (down from ₩560 in 3Q 2022). Revenue: ₩24.1b (up 10% from 3Q 2022). Net income: ₩3.92b (down 37% from 3Q 2022). Profit margin: 16% (down from 28% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Reported Earnings • May 14First quarter 2023 earnings released: EPS: ₩256 (vs ₩153 in 1Q 2022)First quarter 2023 results: EPS: ₩256 (up from ₩153 in 1Q 2022). Revenue: ₩22.4b (up 27% from 1Q 2022). Net income: ₩2.76b (up 61% from 1Q 2022). Profit margin: 12% (up from 9.7% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Upcoming Dividend • Dec 21Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 20 April 2023. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Nov 13Third quarter 2022 earnings released: EPS: ₩560 (vs ₩186 in 3Q 2021)Third quarter 2022 results: EPS: ₩560 (up from ₩186 in 3Q 2021). Revenue: ₩21.8b (up 40% from 3Q 2021). Net income: ₩6.18b (up 198% from 3Q 2021). Profit margin: 28% (up from 13% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • Dec 22Inaugural dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for Jin Yang Pharmaceutical since going public. The average dividend yield among industry peers is 0.8%.Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to ₩6,420, the stock trades at a trailing P/E ratio of 10x. Average trailing P/E is 24x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 86% over the past three years.Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩7,580, the stock trades at a trailing P/E ratio of 20.6x. Average trailing P/E is 24x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 77% over the past three years.Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₩8,300, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 121% over the past three years.분석 기사 • Mar 22A Look At The Intrinsic Value Of Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)In this article we are going to estimate the intrinsic value of Jin Yang Pharmaceutical Co., Ltd. ( KOSDAQ:007370 ) by...분석 기사 • Mar 04Here's Why I Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is An Interesting StockLike a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...Is New 90 Day High Low • Feb 23New 90-day low: ₩5,940The company is down 20% from its price of ₩7,410 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.공시 • Feb 17Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 19, 2021Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 19, 2021, at 09:00 Korea Standard Time.분석 기사 • Feb 11These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt SafelyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Is New 90 Day High Low • Jan 28New 90-day low: ₩6,300The company is down 2.0% from its price of ₩6,440 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.분석 기사 • Jan 21Are Jin Yang Pharmaceutical Co., Ltd.'s (KOSDAQ:007370) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?It is hard to get excited after looking at Jin Yang Pharmaceutical's (KOSDAQ:007370) recent performance, when its stock...분석 기사 • Jan 04Does Jin Yang Pharmaceutical's (KOSDAQ:007370) Share Price Gain of 49% Match Its Business Performance?It hasn't been the best quarter for Jin Yang Pharmaceutical Co., Ltd. ( KOSDAQ:007370 ) shareholders, since the share...Upcoming Dividend • Dec 22Upcoming Dividend of ₩100.00 Per ShareWill be paid on the 13th of April to those who are registered shareholders by the 29th of December. The company last paid an ordinary dividend in April 2010. The average dividend yield among industry peers is 0.6%.분석 기사 • Dec 17We're Not So Sure You Should Rely on Jin Yang Pharmaceutical's (KOSDAQ:007370) Statutory EarningsStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said that...분석 기사 • Nov 30Here's Why We Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is Well Worth WatchingSome have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...Is New 90 Day High Low • Oct 26New 90-day low: ₩6,350The company is down 8.0% from its price of ₩6,900 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.주주 수익률A007370KR PharmaceuticalsKR 시장7D4.6%7.9%-3.6%1Y-40.5%1.1%148.4%전체 주주 수익률 보기수익률 대 산업: A007370은 지난 1년 동안 1.1%의 수익을 기록한 KR Pharmaceuticals 산업보다 저조한 성과를 냈습니다.수익률 대 시장: A007370은 지난 1년 동안 148.4%를 기록한 KR 시장보다 저조한 성과를 냈습니다.주가 변동성Is A007370's price volatile compared to industry and market?A007370 volatilityA007370 Average Weekly Movement5.8%Pharmaceuticals Industry Average Movement6.8%Market Average Movement9.3%10% most volatile stocks in KR Market16.5%10% least volatile stocks in KR Market4.9%안정적인 주가: A007370는 지난 3개월 동안 KR 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: A007370의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트1971n/aJae-Joon Choiwww.jinyangpharm.com진양제약은 한국에서 제약 사업을 하고 있습니다. 이 회사는 크리빅스 정제, 에스졸 정제, 아톨란 정제, 처방약 및 일반 의약품을 제공합니다. 또한 항지혈제, 항혈소판제, 위장 및 호흡기 치료제, 항혈전제, NSAID, 폐경기 증상 치료제, 구강 관련 제품도 제공합니다.더 보기Jin Yang Pharmaceutical Co., Ltd. 기초 지표 요약Jin Yang Pharmaceutical의 순이익과 매출은 시가총액과 어떻게 비교됩니까?A007370 기초 통계시가총액₩50.03b순이익 (TTM)₩22.29b매출 (TTM)₩122.15b2.2x주가수익비율(P/E)0.4x주가매출비율(P/S)A007370는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표A007370 손익계산서 (TTM)매출₩122.15b매출원가₩42.04b총이익₩80.11b기타 비용₩57.82b순이익₩22.29b최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)1.73k총이익률65.58%순이익률18.25%부채/자본 비율47.4%A007370의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당3.9%현재 배당 수익률n/a배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/06 23:53종가2026/07/06 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Jin Yang Pharmaceutical Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
분석 기사 • May 27Beyond Lackluster Earnings: Potential Concerns For Jin Yang Pharmaceutical's (KOSDAQ:007370) ShareholdersJin Yang Pharmaceutical Co., Ltd.'s ( KOSDAQ:007370 ) stock wasn't much affected by its recent lackluster earnings...
Buy Or Sell Opportunity • May 14Now 22% overvaluedOver the last 90 days, the stock has fallen 6.1% to ₩4,695. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 22%.
Buy Or Sell Opportunity • Apr 13Now 20% overvaluedOver the last 90 days, the stock has fallen 4.6% to ₩4,625. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 22%.
New Risk • Mar 27New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 3,533% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩59.6b market cap, or US$39.4m).
Buy Or Sell Opportunity • Mar 20Now 21% overvaluedOver the last 90 days, the stock has fallen 12% to ₩4,640. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 22%.
Buy Or Sell Opportunity • Mar 05Now 20% overvaluedOver the last 90 days, the stock has fallen 12% to ₩4,630. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 22%.
분석 기사 • May 27Beyond Lackluster Earnings: Potential Concerns For Jin Yang Pharmaceutical's (KOSDAQ:007370) ShareholdersJin Yang Pharmaceutical Co., Ltd.'s ( KOSDAQ:007370 ) stock wasn't much affected by its recent lackluster earnings...
Buy Or Sell Opportunity • May 14Now 22% overvaluedOver the last 90 days, the stock has fallen 6.1% to ₩4,695. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 22%.
Buy Or Sell Opportunity • Apr 13Now 20% overvaluedOver the last 90 days, the stock has fallen 4.6% to ₩4,625. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 22%.
New Risk • Mar 27New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 3,533% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩59.6b market cap, or US$39.4m).
Buy Or Sell Opportunity • Mar 20Now 21% overvaluedOver the last 90 days, the stock has fallen 12% to ₩4,640. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 22%.
Buy Or Sell Opportunity • Mar 05Now 20% overvaluedOver the last 90 days, the stock has fallen 12% to ₩4,630. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 22%.
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩4,370, the stock trades at a trailing P/E ratio of 10.2x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 26% over the past three years.
공시 • Feb 24Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2026Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 34, sinpyeong-ro, jijeong-myeon, gangwon-do, wonju South Korea
Upcoming Dividend • Dec 22Upcoming dividend of ₩150 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 20 April 2026. Trailing yield: 2.8%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%).
New Risk • Nov 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.7% Last year net profit margin: 25% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (3.7% operating cash flow to total debt). Minor Risks Profit margins are more than 30% lower than last year (4.7% net profit margin). Market cap is less than US$100m (₩61.9b market cap, or US$42.1m).
Declared Dividend • Nov 08Dividend of ₩150 announcedDividend of ₩150 is the same as last year. Ex-date: 29th December 2025 Payment date: 20th April 2026 Dividend yield will be 2.9%, which is higher than the industry average of 1.1%. Sustainability & Growth The dividend has increased by an average of 11% per year over the past 4 years and payments have been stable during that time.
공시 • Nov 07Jin Yang Pharmaceutical Co., Ltd. announces Annual dividend, payable on April 20, 2026Jin Yang Pharmaceutical Co., Ltd. announced Annual dividend of KRW 150.0000 per share payable on April 20, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
분석 기사 • May 24We Think Shareholders Should Be Aware Of Some Factors Beyond Jin Yang Pharmaceutical's (KOSDAQ:007370) ProfitDespite posting strong earnings, Jin Yang Pharmaceutical Co., Ltd.'s ( KOSDAQ:007370 ) stock didn't move much over the...
공시 • Feb 25Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 20, 2025Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 20, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 34, sinpyeong-ro, jijeong-myeon, gangwon-do, wonju South Korea
분석 기사 • Jan 06Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370) Soars 39% But It's A Story Of Risk Vs RewardDespite an already strong run, Jin Yang Pharmaceutical Co., Ltd. ( KOSDAQ:007370 ) shares have been powering on, with a...
New Risk • Jan 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (70% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (5.9% increase in shares outstanding). Market cap is less than US$100m (₩89.7b market cap, or US$61.5m).
Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improves as stock rises 35%After last week's 35% share price gain to ₩7,850, the stock trades at a trailing P/E ratio of 3.2x. Average trailing P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 21% over the past three years.
Declared Dividend • Dec 19Dividend of ₩150 announcedShareholders will receive a dividend of ₩150. Ex-date: 27th December 2024 Payment date: 1st January 1970 Dividend yield will be 2.5%, which is higher than the industry average of 1.1%. Sustainability & Growth The dividend has increased by an average of 14% per year over the past 3 years and payments have been stable during that time.
Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩6,180, the stock trades at a trailing P/E ratio of 2.5x. Average trailing P/E is 12x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 3.0% over the past three years.
분석 기사 • Nov 22Shareholders Shouldn’t Be Too Comfortable With Jin Yang Pharmaceutical's (KOSDAQ:007370) Strong EarningsEven though Jin Yang Pharmaceutical Co., Ltd. ( KOSDAQ:007370 ) posted strong earnings recently, the stock hasn't...
Reported Earnings • Nov 15Third quarter 2024 earnings released: EPS: ₩2,008 (vs ₩363 in 3Q 2023)Third quarter 2024 results: EPS: ₩2,008 (up from ₩363 in 3Q 2023). Revenue: ₩31.6b (up 31% from 3Q 2023). Net income: ₩22.2b (up 468% from 3Q 2023). Profit margin: 70% (up from 16% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
New Risk • Aug 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 9.5% Last year net profit margin: 18% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (11% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (9.5% net profit margin). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Market cap is less than US$100m (₩64.1b market cap, or US$48.0m).
분석 기사 • Aug 19Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370) Shares Fly 32% But Investors Aren't Buying For GrowthDespite an already strong run, Jin Yang Pharmaceutical Co., Ltd. ( KOSDAQ:007370 ) shares have been powering on, with a...
Valuation Update With 7 Day Price Move • Aug 19Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₩7,250, the stock trades at a trailing P/E ratio of 6.8x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 1.8% over the past three years.
New Risk • Aug 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Market cap is less than US$100m (₩62.0b market cap, or US$45.9m).
분석 기사 • Aug 12These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Reasonably WellHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 • May 23Jin Yang Pharmaceutical's (KOSDAQ:007370) Problems Go Beyond Weak ProfitThe subdued market reaction suggests that Jin Yang Pharmaceutical Co., Ltd.'s ( KOSDAQ:007370 ) recent earnings didn't...
New Risk • Mar 16New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Market cap is less than US$100m (₩63.8b market cap, or US$48.0m).
Upcoming Dividend • Dec 20Upcoming dividend of ₩150 per share at 2.4% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 19 April 2024. Trailing yield: 2.4%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).
Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩363 (vs ₩560 in 3Q 2022)Third quarter 2023 results: EPS: ₩363 (down from ₩560 in 3Q 2022). Revenue: ₩24.1b (up 10% from 3Q 2022). Net income: ₩3.92b (down 37% from 3Q 2022). Profit margin: 16% (down from 28% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Reported Earnings • May 14First quarter 2023 earnings released: EPS: ₩256 (vs ₩153 in 1Q 2022)First quarter 2023 results: EPS: ₩256 (up from ₩153 in 1Q 2022). Revenue: ₩22.4b (up 27% from 1Q 2022). Net income: ₩2.76b (up 61% from 1Q 2022). Profit margin: 12% (up from 9.7% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Upcoming Dividend • Dec 21Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 20 April 2023. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 13Third quarter 2022 earnings released: EPS: ₩560 (vs ₩186 in 3Q 2021)Third quarter 2022 results: EPS: ₩560 (up from ₩186 in 3Q 2021). Revenue: ₩21.8b (up 40% from 3Q 2021). Net income: ₩6.18b (up 198% from 3Q 2021). Profit margin: 28% (up from 13% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • Dec 22Inaugural dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for Jin Yang Pharmaceutical since going public. The average dividend yield among industry peers is 0.8%.
Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to ₩6,420, the stock trades at a trailing P/E ratio of 10x. Average trailing P/E is 24x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 86% over the past three years.
Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩7,580, the stock trades at a trailing P/E ratio of 20.6x. Average trailing P/E is 24x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 77% over the past three years.
Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₩8,300, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 121% over the past three years.
분석 기사 • Mar 22A Look At The Intrinsic Value Of Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)In this article we are going to estimate the intrinsic value of Jin Yang Pharmaceutical Co., Ltd. ( KOSDAQ:007370 ) by...
분석 기사 • Mar 04Here's Why I Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is An Interesting StockLike a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Is New 90 Day High Low • Feb 23New 90-day low: ₩5,940The company is down 20% from its price of ₩7,410 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.
공시 • Feb 17Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 19, 2021Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 19, 2021, at 09:00 Korea Standard Time.
분석 기사 • Feb 11These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt SafelyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Is New 90 Day High Low • Jan 28New 90-day low: ₩6,300The company is down 2.0% from its price of ₩6,440 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.
분석 기사 • Jan 21Are Jin Yang Pharmaceutical Co., Ltd.'s (KOSDAQ:007370) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?It is hard to get excited after looking at Jin Yang Pharmaceutical's (KOSDAQ:007370) recent performance, when its stock...
분석 기사 • Jan 04Does Jin Yang Pharmaceutical's (KOSDAQ:007370) Share Price Gain of 49% Match Its Business Performance?It hasn't been the best quarter for Jin Yang Pharmaceutical Co., Ltd. ( KOSDAQ:007370 ) shareholders, since the share...
Upcoming Dividend • Dec 22Upcoming Dividend of ₩100.00 Per ShareWill be paid on the 13th of April to those who are registered shareholders by the 29th of December. The company last paid an ordinary dividend in April 2010. The average dividend yield among industry peers is 0.6%.
분석 기사 • Dec 17We're Not So Sure You Should Rely on Jin Yang Pharmaceutical's (KOSDAQ:007370) Statutory EarningsStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said that...
분석 기사 • Nov 30Here's Why We Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is Well Worth WatchingSome have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...
Is New 90 Day High Low • Oct 26New 90-day low: ₩6,350The company is down 8.0% from its price of ₩6,900 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
